PREDICTING HUMAN TUMOR RESPONSE BY 31P MRS

通过 31P MRS 预测人类肿瘤反应

• 批准号: 2103872
• 负责人: JEFFREY L EVELHOCH
• 金额: $ 10万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-05-26 至 2000-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2103872
• 关键词: acidity /alkalinity; breast neoplasms; cooperative study; creatine phosphate; head /neck neoplasm; human subject; human therapy evaluation; metabolism; neoplasm /cancer therapy; nonHodgkin's lymphoma; nuclear magnetic resonance spectroscopy; phospholipids; phosphorus; prognosis; radionuclides; sarcoma

DESCRIPTION: This application from CCCMH, Detroit, Michigan. The 31-P Magnetic Resonance Spectroscopy (MRS) of human cancers in vivo typically have metabolic characteristics which differ from those of normal tissues. These include elevations of phosphomonoesters (PME), phosphodiesters (PDE), and cellular pH, and dimished phosphocreatine (PCr). These characteristics have been shown to provide useful prognostic indices and predictors of sensitivity to radiotherapy combined with hyperthermia in soft tissue sarcomas. This background indicates that it would now be appropriate to examine the clinical utility of MRS in the management of cancer patients. The study proposed in this application is a cooperative prospective trial in a large number of patients with types of cancers especially well suited to address this issue. This proposal is one of 8 Interactive R01 applications from 8 institutions collaborating to study over 1400 patients with non- Hodgkin's lymphomas, locally advanced primary breast cancers, soft tissue sarcomas, and carcinomas of the head and neck. Careful attention will be paid to patient selection, protocol management, technical quality control and group statistical analysis. State-of-the-art techniques have been or will be established at all institutions, to include: dual tuned 1H 31-P surface coils needed to access the wide variety of anatomic locations of these cancers; proton decoupling of 31- P to distinguish individual components of phospholipid metabolites; image guided 3 dimensional chemical shift imaging to accurately localize 31-P MR spectra to tumor masses; absolute quantitation of metabolites; and pattern recognition of spectra. The applicants will test the hypothesis that the in vivo 31-P Mr spectrum can predict the sensitivity or resistance to treatment by correlating the initial response to metabolic features in the baseline spectrum and to changes that occur in the spectrum early after the initiation of treatment. The applicants will also test the hypothesis that 31-P MRS contains prognostic information by correlating disease-free survival in responders, and where feasible overall survival, to metabolic features in the baseline and followup spectra. This study will establish standards for cooperative MRS trials in other cancers and clinical settings, and will pave the way for clinical trials in which MRS could be used to intervene in the selection of treatment regimens in individual cancer patients.

描述：此申请来自密歇根州底特律的CCCMH。 31-P 人体内人类癌的磁共振光谱（MRS）通常是 具有代谢特征与正常特征不同 组织。 其中包括磷龙植物（PME）的升高 磷酸化剂（PDE）和细胞pH，并二聚磷酸蛋白 （PCR）。 这些特征已证明提供了有用的 对放射疗法敏感性的预后指标和预测指标 与软组织肉瘤中的热疗结合。 这个背景 表明现在检查临床是合适的 MRS在癌症患者管理中的效用。 该研究提出了 在此申请中是一项合作的前瞻性试验 癌症类型的患者特别适合解决此问题 问题。 该提案是8个互动R01应用程序之一 机构合作研究1400多名非 - 霍奇金的淋巴瘤，局部先进的原发性乳腺癌，柔软 组织肉瘤和头颈的癌。 仔细注意 将支付给患者选择，协议管理，技术 质量控制和小组统计分析。 最先进的 技术已经或将在所有机构中建立 包括：访问宽的双重调谐1H 31-P表面线圈 这些癌症的各种解剖位置； 31-的质子脱钩 p以区分磷脂代谢产物的各个成分；图像 指导3尺寸化学移动成像以准确定位31-P Mr Spectra to肿瘤质量；代谢物的绝对定量；和 光谱的模式识别。 申请人将测试 假设体内31-P MR光谱可以预测灵敏度 或通过将初始反应与 基线光谱中的代谢特征和发生的变化 在开始治疗后早期的光谱中。 这 申请人还将检验31-P MRS包含的假设 通过将无病生存相关的预后信息 响应者以及可行的整体生存，具有代谢特征 在基线和后续光谱中。 这项研究将建立 其他癌症和临床的合作MRS试验标准 设置，并将为MRS可以的临床试验铺平道路 用于干预治疗方案的选择 个别癌症患者。